Polling conducted across six European countries, with over 6,000 respondents, finds high levels of excitement for gene therapy and medical innovation, particularly for the treatment of rare diseases.
Over the past ten years 11 gene therapies have received marketing authorisation from the European Medicines Agency (EMA) and it is anticipated that between 10 and 20 new transformative therapies will be approved each year from 2025.
Yet according to a major new survey of 6,250 EU and British Citizens commissioned by biopharmaceutical company BioMarin, over half (54%) of respondents are concerned that research into breakthrough medical technologies may have been paused or deprioritised over the past two years during COVID-19. Only 43% of respondents are now confident their government or local health authority will make a gene therapy available once approved for use.